Uncategorised

In November 2022, a new RECOVER paper was published titled ‘Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna’. The aim of the study was to investigate how targeted use of nirmatrelvir/ritonavir can complement vaccination and non-pharmaceutical interventions (NPIs), and mitigate the epidemic rebound expected when Zero-COVID ends.

In October 2022, a RECOVER paper was published on the outbreak of the SARS-CoV-2 Alpha variant in a Dutch primary school. The RECOVER team studied this outbreak, retrospectively and prospectively from December 2020 until February 2021, by using population-based screening. The aim was to get a better understanding of the disease severity and transmission of the Alpha variant.

Ecraid augments its response to the expanding monkeypox outbreak in Europe. These preparations are proportionate to the current perceived risk of this infection for European citizens. Ecraid is now operating in outbreak response mode 3 (response) for adults, and in outbreak response mode 2 (mobilisation) for children, the third and second of three response modes.

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), one of our partners within the RECOVER Consortium, has recently published a new paper on COVID-19 data. The report focuses on a prospective, standardised, global dataset of patients that were hospitalised with COVID-19.

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), one of our partners within the RECOVER Consortium, has recently published a new paper on COVID-19 data. The report focuses on a prospective, standardised, global dataset of patients that were hospitalised with COVID-19.

The impacts of healthcare professionals being research participants are often neglected. As professionals, they tend to be perceived as ‘immune’ to many negative effects of sharing their experiences. However, in the context of an ongoing global pandemic such as COVID-19, these assumptions can be clearly challenged. In March 2022, the RECOVER Social Science team, together with other collaborators, published a new article that draws on their experiences of conducting single and longitudinal qualitative interviews with Health Care Professionals (HCP) in primary, secondary and tertiary settings during the COVID-19 pandemic in Europe during 2020.

The impacts of healthcare professionals being research participants are often neglected. As professionals, they tend to be perceived as ‘immune’ to many negative effects of sharing their experiences. However, in the context of an ongoing global pandemic such as COVID-19, these assumptions can be clearly challenged. In March 2022, the RECOVER Social Science team, together with other collaborators, published a new article that draws on their experiences of conducting single and longitudinal qualitative interviews with Health Care Professionals (HCP) in primary, secondary and tertiary settings during the COVID-19 pandemic in Europe during 2020.

On the 1st of January 2022, the Ecraid foundation was formerly launched. Ecraid advances clinical research in the field of infectious disease with the development of a pan-European clinical research network. It is the first network of its kind in Europe. MERMAIDS, SOS-COVID and REMAP-CAP, the clinical studies that have been included as part of the HORIZON2020 funded RECOVER project on COVID-19 are embedded into Ecraid.

At the beginning of 2022, the SARS-CoV-2 pandemic has not stopped yet. Despite high vaccination coverage, the number of positive cases has reached a record level. In addition, a new SARS-CoV-2 variant has emerged (Omicron variant) with a higher infection rate compared to previous variants. Both of these aspects may have a significant effect on the transmission of SARS-CoV-2 within households. However, the extent of that effect has not yet been quantified. Therefore, a new study to analyse the transmission of SARS-CoV-2 infections within households was launched in January 2022.

At the beginning of 2022, the SARS-CoV-2 pandemic has not stopped yet. Despite high vaccination coverage, the number of positive cases has reached a record level. In addition, a new SARS-CoV-2 variant has emerged (Omicron variant) with a higher infection rate compared to previous variants. Both of these aspects may have a significant effect on the transmission of SARS-CoV-2 within households. However, the extent of that effect has not yet been quantified. Therefore, a new study to analyse the transmission of SARS-CoV-2 infections within households was launched in January 2022.